跳至主要内容
临床试验/NCT02478151
NCT02478151Unknown1 期

A Single Centre Study of the Feasibility and Safety of Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation

University Health Network, Toronto2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2015年7月最近更新:
适应症

试验速览

阶段
1 期
入组人数
40
试验地点
2
主要终点
Rates of recipient death

研究概览

简要总结

This trial will examine the safety and feasibility of using the OrganOx Metra device to transport and store donor livers under normothermic conditions prior to transplantation. Participants will be followed for 3 months following transplantation and their outcomes recorded.

详细描述

Liver transplantation is a life-saving procedure but its success has been limited by a shortage of suitable donor organs. Much emphasis is now placed on optimising the condition of those organs that are available, to enable more higher risk organs to be transplanted safely. An effective means of pre-transplant viability assessment would not only allow greater use of higher risk donors but also minimise the risk of primary non-function by identifying and excluding non-viable organs before subjecting a patient to the risk of surgery. Organ storage under normothermic perfusion conditions enables organ function to be evaluated prior to transplantation and further has been shown to prevent organ injury which is sustained during standard cold storage. This trial will examine the safety and feasibility of using the OrganOx Metra device to transport and store donor livers under normothermic conditions prior to transplantation. This study will evaluate liver function post-transplantation using standard clinical parameters. Participants will be followed for 3 months following transplantation and their outcomes recorded. Participants will undergo no other study procedures. Feasibility will be measured using the ratio of actual / eligible candidate donors recruited to the study and will also encompass logistical issues with respect to transportation, and ease of use. Safety will be assessed by rates of device failures resulting in organ discard, primary graft non-function, re-transplantation, and recipient death.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (18 years or more)
  • Active on the waiting list for liver transplantation
  • Able to give informed consent

排除标准

  • Age less than 18 years
  • Acute/fulminant liver failure
  • Transplantation of more than one organ (e.g. liver and kidney)
  • Refusal of informed consent
  • Unable to give informed consent
  • Re-transplantation Diagnosis of Hepatopulmonary Syndrome

结局指标

主要结局

Rates of recipient death

时间窗: 3 months

Rates of primary graft non-function

时间窗: 3 months

Rates of re-transplantation

时间窗: 3 months

次要结局

  • Recruitment rates to the study(3 months)
  • Rate of device failures resulting in organ discard(3 months)
  • The ability of perfusion parameters to predict clinical outcomes following transplantation(3 months)
  • Ischemia- reperfusion injury associated with organ storage(7 days)
  • The function of liver grafts stored with the Metra™ device(3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验